智通财经网·2026-03-30 13:23Financial Performance - The company reported a revenue of 283.58 billion RMB for the fiscal year 2025, representing a year-on-year growth of 3.03% [1] - The pharmaceutical manufacturing segment achieved sales revenue of 24.52 billion RMB, up 3.33% year-on-year, while the pharmaceutical commercial segment generated sales of 259.06 billion RMB, also increasing by 3.00% [1] - Net profit attributable to shareholders was 5.73 billion RMB, a significant increase of 25.74% year-on-year, primarily due to a one-time special gain from changing the accounting treatment of a joint venture to a subsidiary [1] - After excluding one-time special gains, the adjusted net profit attributable to shareholders was 4.72 billion RMB, reflecting a decline of 5.56% year-on-year [1] R&D and Innovation - The company successfully launched the innovative drug Apixaban, providing a new treatment option for over 300 million patients with primary hypertension, marking a significant achievement in its innovation efforts [2] - The global innovative anti-CD20 antibody drug B001 has completed the primary endpoint analysis of its key study, while the traditional Chinese medicine for cervical spondylotic myelopathy has completed all cases in its Phase III clinical trial [2] - The company is advancing several other drugs in Phase III clinical trials, including SHPL-49 for acute ischemic stroke and SRD4610 for amyotrophic lateral sclerosis, indicating a robust pipeline [2] - The company is enhancing its innovation ecosystem by integrating resources from academia, research, and industry, and is building a collaborative research management system with institutions like Shanghai Jiao Tong University [2]